The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines

@article{Nishimura2007TheEI,
  title={The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines},
  author={Yukio Nishimura and B{\'i}borka Bereczky and Michiko Ono},
  journal={Histochemistry and Cell Biology},
  year={2007},
  volume={127},
  pages={541-553}
}
The drug gefitinib (Iressa), which is a specific inhibitor of EGFR tyrosine kinase, has been shown to suppress the activation of EGFR signaling for survival and proliferation in non-small cell lung cancer (NSCLC) cell lines. A recent study demonstrated rapid down-regulation of ligand-induced EGFR in a gefitinib-sensitive cell line and inefficient down-regulation of EGFR in a gefitinib-resistant cell line in the exponential phase of growth; this implies that each cell type employs a different… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Cellular targets of geWtinib

  • D Brehmer, Z GreV, +9 authors H Daub
  • Cancer Res
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…